Introduction.
Department of Medicine, University of Otago, Christchurch, New Zealand. Richard.Gearry@cdhb.health.nz.
Richard B
RB
Gearry
D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D005290:Ferric Compounds / Q000008:administration & dosage*; D006268:Health Facilities; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000451:nursing* / Q000628:therapy*; D000069285:Infliximab / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008320:Maltose / Q000008:administration & dosage / Q000031:analogs & derivatives*; D010349:Patient Compliance; D010353:Patient Education as Topic
D061067:Antibodies, Monoclonal, Humanized; D005290:Ferric Compounds; C522335:ferric carboxymaltose; D008320:Maltose; C543529:vedolizumab; D000069285:Infliximab